Insider Selling: uniQure (NASDAQ:QURE) Insider Sells $23,809.38 in Stock

uniQure (NASDAQ:QUREGet Free Report) insider Jeannette Potts sold 4,781 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $4.98, for a total transaction of $23,809.38. Following the completion of the transaction, the insider now owns 91,819 shares of the company’s stock, valued at approximately $457,258.62. The sale was disclosed in a filing with the SEC, which is available at this link.

uniQure Trading Down 2.6 %

QURE stock opened at $4.57 on Thursday. The company has a fifty day moving average of $4.86 and a 200-day moving average of $5.59. The company has a debt-to-equity ratio of 0.70, a quick ratio of 9.27 and a current ratio of 9.39. uniQure has a one year low of $4.25 and a one year high of $19.63.

uniQure (NASDAQ:QUREGet Free Report) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The business had revenue of $8.49 million for the quarter, compared to analysts’ expectations of $2.58 million. Research analysts forecast that uniQure will post -4.5 EPS for the current year.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently added to or reduced their stakes in the business. Raymond James & Associates increased its holdings in uniQure by 6.4% during the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of uniQure by 58.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 3,664 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of uniQure by 21.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 5,389 shares during the last quarter. Pale Fire Capital SE boosted its stake in shares of uniQure by 9.2% during the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 5,500 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of uniQure by 8.0% during the 3rd quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 7,400 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on QURE. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Wednesday, May 8th. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $63.00 to $8.00 in a research note on Thursday, February 29th. Mizuho decreased their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.75.

Read Our Latest Stock Analysis on QURE

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

See Also

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.